Table 2.
Treatment response with Duloxetine for panic disorder (n= 15)
| Instrument | Baseline Mean ± SD | Endpoint Mean ± SD | t(df) | Significance P |
|---|---|---|---|---|
| PDSS | 14.2 ± 4.28 | 9.13 ± 5.26 | 4.02 (14) | 0.0013 |
| PAS attacks/week | 3.90 ± 2.38 | 0.90 ± 1.44 | 6.06 (14) | 0.00001 |
| MADRS | 15.1 ± 7.08 | 9.07 ± 6.68 | 4.30 (14) | 0.0007 |
| CGI‐S | 4.80 ± 0.67 | 3.47 ± 1.30 | 4.64 (14) | 0.0004 |
| BAI | 28.1 ± 10.6 | 14.7 ± 13.7 | 3.83 (12) | 0.0024 |
| QLESQ | 41.3 ± 8.28 | 49.3 ± 12.8 | −3.03 (14) | 0.0091 |
| SDS | 17.4 ± 5.57 | 9.40 ± 8.61 | 3.07 (14) | 0.0083 |
| LIFE‐RIFT | 11.7 ± 2.23 | 9.33 ± 3.63 | 2.65 (11) | 0.0228 |
BAI = beck anxiety inventory; CGI‐S = clinical global impressions‐severity of illness scale; LIFE‐RIFT = longitudinal interval follow‐up evaluation range of impaired functioning tool; MADRS = montgomery‐Asberg depression rating scale, PAS = panic attack scale, PDSS = panic disorder severity scale, QLESQ = qualtiy of life and enjoyment and satisfaction questionnaire, SDS = Sheehan disability scale.